The company’s distribution partner in China coordinated seminars and hands-on laboratory experiences for surgeons to learn about the Renaissance system. Mazor has seven Renaissance systems installed throughout Asia.
“China continues to adopt proven and state-of-the-art technologies to offer better patient outcomes, so we believe Renaissance is well-positioned to gain market acceptance. Our distribution partner, Cicel, believes the target market for Renaissance is in the hundreds of hospitals in China. Now, with the CFDA approval, our partner will initiate its marketing and sales process to introduce Renaissance to this important market. Cicel has the local market knowledge and expertise along with the sales, marketing and clinical organization to quickly raise awareness of the Renaissance system,” said Ori Hadomi, CEO of Mazor.
More articles on devices:
A 5-year spine-device warranty? Titan Spine is all in
PODs under attack — 5 things to know
39 orthopedic, spine devices receive FDA 510(k) clearance in August
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
